Consensus Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 01:29:21 2025-04-17 pm EDT			5-day change	1st Jan Change
7.705 ^USD	-2.59%		-2.77%	-43.62%

Apr. 09	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT
Apr. 07	Myriad Genetics Names Brian Donnelly As New Chief Commercial Officer	RE

Evolution of the Average Target: Myriad Genetics, Inc.

Evolution of the Target Price: Myriad Genetics, Inc.

Changes in Analyst Recommendations: Myriad Genetics, Inc.

523.wo8tAPDYDqAx7bnf_ulFRthxZfVNkNzs5DPFKBhIrIE.-9ZjMabrZOYGg_WvlIYtLb0eApd884WIsFefd2sD_ueAt0YxmpdL-lqM3g~b2fb8c4bcfbe933a856e1ddd9582b6b0

Analysts' recommendations: Myriad Genetics, Inc.

Guggenheim Downgrades Myriad Genetics to Neutral From Buy	Apr. 09	MT
Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	Mar. 12	MT
UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	Feb. 25	MT
Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	Dec. 09	MT
Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	Nov. 18	MT
Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	24-09-19	MT
Morgan Stanley Initiates Myriad Genetics at Equalweight	24-09-19	MT
Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target	24-08-28	MT
Scotiabank Initiates Myriad Genetics at Sector Outperform	24-06-27	MT
Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	24-05-13	MT
Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	24-01-29	MT
BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating	24-01-29	MT
Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target	23-12-19	MT
Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target	23-12-13	MT
BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating	23-10-20	MT
JPMorgan Adjusts Myriad Genetics' Price Target to $17 From $18, Keeps Underweight Rating	23-08-07	MT
Goldman Sachs Adjusts Price Target on Myriad Genetics to $28 From $25, Maintains Buy Rating	23-07-21	MT
Goldman Sachs Upgrades Myriad Genetics to Buy From Sell, Raises Price Target to $25 From $18	23-05-23	MT
Analyst recommendations: Chevron, Deere & Co, Nvidia, Steel Dynamics...	23-05-23
Jefferies Raises Myriad Genetics' Price Target to $22 From $19, Hold Rating Kept	23-05-04	MT
Morningstar Downgrades Myriad Genetics to Sell From Hold, $18.50 Price Target	23-05-04	MT
Goldman Sachs Cuts Myriad Genetics' Price Target to $18 From $20, Sell Rating Kept	23-05-04	MT
Stephens Adjusts Price Target on Myriad Genetics to $24 From $17, Maintains Equal-Weight Rating	23-03-06	MT
Raymond James Adjusts Price Target on Myriad Genetics to $27 From $25, Maintains Outperform Rating	23-03-03	MT
Raymond James Upgrades Myriad Genetics to Outperform From Market Perform, Price Target is $25	23-01-18	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	MYRIAD GENETICS, INC.					+102.35%
	BIOMÉRIEUX					+5.72%
	LANTHEUS HOLDINGS, INC.					+33.69%
	DIASORIN S.P.A.					+11.85%
	GUARDANT HEALTH, INC.					+25.53%
	SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.					+63.11%
	AUTOBIO DIAGNOSTICS CO., LTD.					+36.09%
	VITROLIFE AB					+61.14%
	SANSURE BIOTECH INC.					+28.75%
	Average					+40.92%
	Weighted average by Cap.					+26.23%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.910USD

Average target price

16.01USD

Spread / Average Target

+102.35%

High Price Target

29.00USD

Spread / Highest target

+266.62%

Low Price Target

9.000USD

Spread / Lowest Target

+13.78%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Guggenheim
Piper Sandler
UBS
Leerink Partners
Morgan Stanley
BofA Securities
Goldman Sachs
Wells Fargo Securities
Wolfe Research
JPMorgan Chase
Morningstar
Jefferies & Co.
Stephens Inc.
Raymond James
SVB Securities LLC